Emerging therapeutic targets, including novel antiplatelet and anti-inflammatory agents, offer promising avenues for advancing acute coronary syndrome treatment strategies.
This review highlights emerging therapeutic targets for acute coronary syndromes, emphasizing the potential of novel antiplatelet and anti-inflammatory agents while noting the challenges of translating preclinical findings to clinical practice.
Acute coronary syndrome (ACS) remains a major cause of morbidity and mortality worldwide, requiring ongoing efforts to identify novel therapeutic targets to improve patient outcomes. This manuscript reviews promising therapeutic targets for ACS identified through preclinical research, including novel antiplatelet agents, anti-inflammatory drugs, and agents targeting plaque stabilization. Preclinical studies have expounded these agents' efficacy and safety profiles in mitigating key pathophysiological processes underlying ACS, such as platelet activation, inflammation, and plaque instability. Furthermore, ongoing clinical trials are evaluating the efficacy and safety of these agents in ACS patients, with potential implications for optimizing ACS management. Challenges associated with translating preclinical findings into clinical practice, including patient heterogeneity and trial design considerations, are also discussed. Overall, the exploration of emerging therapeutic targets offers promising avenues for advancing ACS treatment strategies and improving patient outcomes.
Mitsis et al. (Fri,) conducted a review in Acute coronary syndrome (ACS). Emerging therapeutic targets (novel antiplatelet agents, anti-inflammatory drugs, plaque stabilization agents) was evaluated. Emerging therapeutic targets, including novel antiplatelet and anti-inflammatory agents, offer promising avenues for advancing acute coronary syndrome treatment strategies.